Regencell Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGC?
Source: Globenewswire
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all investors who purchased Regencell (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, alleging undisclosed market manipulation risks.
- Risk Disclosure: The complaint highlights that the volatility of Regencell's ordinary shares exposed investors to significant financial risks, and the failure to disclose these risks could lead to regulatory scrutiny and legal liabilities, impacting the company's reputation.
- Legal Consequences: Given that the defendants' public statements were deemed materially false and misleading during the relevant period, investors may face legal and financial losses, with the lawsuit potentially resulting in substantial damages for the company.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston law firm before the June 23, 2026, lead plaintiff motion deadline to ensure their rights are protected in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all investors who purchased Regencell (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, alleging undisclosed market manipulation risks.
- Risk Disclosure: The complaint highlights that the volatility of Regencell's ordinary shares exposed investors to significant financial risks, and the failure to disclose these risks could lead to regulatory scrutiny and legal liabilities, impacting the company's reputation.
- Legal Consequences: Given that the defendants' public statements were deemed materially false and misleading during the relevant period, investors may face legal and financial losses, with the lawsuit potentially resulting in substantial damages for the company.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston law firm before the June 23, 2026, lead plaintiff motion deadline to ensure their rights are protected in the class action.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks, reflecting deficiencies in corporate governance and compliance policies.
- Increased Regulatory Risks: Due to the volatility faced by the company, the lawsuit indicates that Regencell may be subjected to heightened regulatory scrutiny and enforcement actions, potentially leading to significant legal, financial, and reputational harm, further impacting investor confidence.
- Investor Call to Action: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, underscoring the case's significance and potential impact on investors.
See More
Regencell Bioscience Holdings Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings (NASDAQ: RGC) about a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline of June 23, 2026, to file a lead plaintiff motion.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions against the company.
- Rising Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating that the company expects to incur substantial legal costs and may face fines exceeding its insurance coverage.
- Stock Price Plunge: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting strong market concerns regarding the company's future prospects.
See More
Regencell Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Regencell Bioscience Holdings Limited is facing a class action lawsuit alleging false and misleading statements regarding its business and compliance policies, exposing shareholders to significant financial risks due to market manipulation vulnerabilities.
- Market Volatility Impact: The volatility in Regencell's ordinary shares has resulted in substantial financial losses for investors, increasing the company's exposure to regulatory scrutiny and potential legal, monetary, and reputational harm.
- Legal Consultation Information: Investors who purchased Regencell shares between October 28, 2024, and October 31, 2025, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek lead plaintiff status in the case.
- Lawsuit Deadline: The deadline to apply for lead plaintiff status is June 23, 2026, and Holzer & Holzer, established in 2000, has successfully recovered hundreds of millions for shareholders affected by corporate misconduct, highlighting their expertise in securities litigation.
See More
U.S. Markets Closed Tuesday with Mixed Results as Paramount Skydance Outperformed and Axon Enterprise Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. ended the day mixed on Tuesday.
- Index Movements: The S&P 500 gained 0.10%, while the Dow Jones rose 0.08%, and the Nasdaq dropped 0.18%.
See More
U.S. Markets Increased on Monday; QXO Saw the Largest Gain
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Monday, with the S&P 500 rising by 1.38%.
- Index Movements: The Dow Jones Industrial Average also increased by 1.38%, while the Nasdaq Composite saw a rise of 1.15%.
See More
Regencell Faces Securities Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for Maryland on behalf of all investors who purchased Regencell (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, alleging undisclosed market manipulation risks.
- Risk Disclosure: The complaint highlights that the volatility of Regencell's ordinary shares exposed investors to significant financial risks, and the failure to disclose these risks could lead to regulatory scrutiny and legal liabilities, impacting the company's reputation.
- Legal Consequences: Given that the defendants' public statements were deemed materially false and misleading during the relevant period, investors may face legal and financial losses, with the lawsuit potentially resulting in substantial damages for the company.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston law firm before the June 23, 2026, lead plaintiff motion deadline to ensure their rights are protected in the class action.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks, reflecting deficiencies in corporate governance and compliance policies.
- Increased Regulatory Risks: Due to the volatility faced by the company, the lawsuit indicates that Regencell may be subjected to heightened regulatory scrutiny and enforcement actions, potentially leading to significant legal, financial, and reputational harm, further impacting investor confidence.
- Investor Call to Action: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, underscoring the case's significance and potential impact on investors.
See More
Regencell Bioscience Holdings Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings (NASDAQ: RGC) about a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline of June 23, 2026, to file a lead plaintiff motion.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions against the company.
- Rising Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating that the company expects to incur substantial legal costs and may face fines exceeding its insurance coverage.
- Stock Price Plunge: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting strong market concerns regarding the company's future prospects.
See More
Regencell Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Regencell Bioscience Holdings Limited is facing a class action lawsuit alleging false and misleading statements regarding its business and compliance policies, exposing shareholders to significant financial risks due to market manipulation vulnerabilities.
- Market Volatility Impact: The volatility in Regencell's ordinary shares has resulted in substantial financial losses for investors, increasing the company's exposure to regulatory scrutiny and potential legal, monetary, and reputational harm.
- Legal Consultation Information: Investors who purchased Regencell shares between October 28, 2024, and October 31, 2025, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek lead plaintiff status in the case.
- Lawsuit Deadline: The deadline to apply for lead plaintiff status is June 23, 2026, and Holzer & Holzer, established in 2000, has successfully recovered hundreds of millions for shareholders affected by corporate misconduct, highlighting their expertise in securities litigation.
See More
U.S. Markets Closed Tuesday with Mixed Results as Paramount Skydance Outperformed and Axon Enterprise Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. ended the day mixed on Tuesday.
- Index Movements: The S&P 500 gained 0.10%, while the Dow Jones rose 0.08%, and the Nasdaq dropped 0.18%.
See More
U.S. Markets Increased on Monday; QXO Saw the Largest Gain
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Monday, with the S&P 500 rising by 1.38%.
- Index Movements: The Dow Jones Industrial Average also increased by 1.38%, while the Nasdaq Composite saw a rise of 1.15%.
See More
